RRC ID 66241
著者 Uemura K, Sasaki M, Sanaki T, Toba S, Takahashi Y, Orba Y, Hall WW, Maenaka K, Sawa H, Sato A.
タイトル MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2.
ジャーナル Sci Rep
Abstract Although the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in a worldwide pandemic, there are currently no virus-specific drugs that are fully effective against SARS-CoV-2. Only a limited number of human-derived cells are capable of supporting SARS-CoV-2 replication and the infectivity of SARS-CoV-2 in these cells remains poor. In contrast, monkey-derived Vero cells are highly susceptibility to infection with SARS-CoV-2, although they are not suitable for the study of antiviral effects by small molecules due to their limited capacity to metabolize drugs compared to human-derived cells. In this study, our goal was to generate a virus-susceptible human cell line that would be useful for the identification and testing of candidate drugs. Towards this end, we stably transfected human lung-derived MRC5 cells with a lentiviral vector encoding angiotensin-converting enzyme 2 (ACE2), the cellular receptor for SARS-CoV-2. Our results revealed that SARS-CoV-2 replicates efficiently in MRC5/ACE2 cells. Furthermore, viral RNA replication and progeny virus production were significantly reduced in response to administration of the replication inhibitor, remdesivir, in MRC5/ACE2 cells compared with Vero cells. We conclude that the MRC5/ACE2 cells will be important in developing specific anti-viral therapeutics and will assist in vaccine development to combat SARS-CoV-2 infections.
巻・号 11(1)
ページ 5376
公開日 2021-3-8
DOI 10.1038/s41598-021-84882-7
PII 10.1038/s41598-021-84882-7
PMID 33686154
PMC PMC7940632
MeSH Angiotensin-Converting Enzyme 2 / metabolism* Animals Antiviral Agents / pharmacology* Antiviral Agents / therapeutic use COVID-19 Drug Treatment Cell Engineering* Cell Line Drug Discovery* Humans Models, Biological* SARS-CoV-2 / drug effects SARS-CoV-2 / physiology* Viral Proteins / biosynthesis Virus Replication / drug effects
IF 3.998
リソース情報
ヒト・動物細胞 CACO-2(RCB0988) 293T(RCB2202)